[A trial of treatment with thymus factor (TFX) for chronic autoimmune hemolytic anemias].
30 days treatment TFX was performed in 8 cases AIHA (autoimmune hemolytic anemia) with presence of warm antibodies refractory after routine treatment (glucocorticosteroids, azathioprine, splenectomy): After TFX treatment in 2 cases autoantibodies were not detectable, in 5 cases reaction DAT (direct antiglobulin test) was decreased. Eluate antibody level and serum antibody level were decreased, too. Decreasing amount of red cells autoantibodies was confirmed by enzyme-linked antiglobulin test (ELAT) in 2 cases. Autoantibody level measured by semiquantitative and quantitative methods did not increase in any other case. Adverse effects of TFX treatment were not observed.
Słomkowski
M
M
Kliniki Hematologicznej Instytutu Hematologii i Transfuzjologii w Warszawie.
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy* / Q000276:immunology; D001323:Autoantibodies / Q000032:analysis / Q000187:drug effects; D004906:Erythrocyte Count / Q000187:drug effects; D006801:Humans; D013949:Thymus Extracts / Q000627:therapeutic use*
D001323:Autoantibodies; C019108:TFX; D013949:Thymus Extracts